Ceftron® is indicated for the treatment of the following major infections when caused by
susceptible organisms: Renal and urinary tract infections, Lower respiratory tract infections,
particularly pneumonia, Gonococcal infections, Skin and soft tissue, bone and joint infections,
Bacterial meningitis, Serious bacterial infections e.g. septicemia, ENT infections, Infections in
cancer patients, Prevention of postoperative infection, Perioperative prophylaxis of infections
associated with surgery,Typhoid fever
DOSAGE AND ADMINISTRATION
Ceftron® (ceftriaxone) can be administered either intravenously or intramuscularly. When
reconstituted for intramuscular or intravenous injection,the white to yellowish-orange crystalline
powder gives a pale yellow to amber solution. Adults: The usual adult daily dose is 1-2 g once
daily, (or twice daily in equally divided doses) depending on the type and severity of infection.
The daily dose may be increased, but should not exceed 4 g. For preoperative use (surgical
prophylaxis), a single dose of 1 gm administered intravenously 0.5-2 hours before surgery is
recommended. In elderly patients, the dosages do not require modification provided that renal
and hepatic functions are satisfactory. In patients with impaired renal function, there is no need
to reduce the dosage of Ceftron® provided liver function is intact. In patients with liver damage,
there is no need for the dosage to be reduced provided renal function is intact. Gonorrhea: For
the treatment of gonorrhea (penicillinase producing and non-penicillinase producing strains), a
single intramuscular dose of 250 mg is recommended. Children under 12 years: The
recommended total daily dose is 50 to 75 mg/kg once daily (or twice daily in equally divided
doses). In severe infections, up to 80 mg/kg body weight daily may be given. The total daily dose
should not exceed 2 gm. In the treatment of meningitis, the initial dose of 100 mg/kg body
weight (not to exceed 4 gm daily) once daily (or twice daily in equally divided doses), is
recommended. As soon as the causative organism has been identified and its sensitivity, the
doses can be reduced accordingly.The usual duration of therapy in meningitis is 7 to 14 days.
CONTRAINDICATION AND PRECAUTION
Ceftron® should not be given to patients with a history of hypersensitivity to cephalosporin
antibiotics. It is contraindicated in premature infants during the first 6 weeks of life. Its safety in
human pregnancy has not been established. Ceftriaxone is contraindicated in neonates if they
require (or are expected to require) treatment with calcium-containing IV solutions, including
continuous calcium-containing infusions such as parenteral nutrition because of the risk of
precipitation of ceftriaxone-calcium.
Ceftron® is generally well tolerated. A few side-effects such as 1. Gastrointestinal effects include
diarrhea, nausea and vomiting, stomatitis and glossitis 2. Cutaneous reactions include rash,
pruritus, urticaria, edema & erythema multiforme 3.Hematological reactions include eosinophilia,
thrombocytosis, leukopenia, and neutropenia 4. Hepatic reactions include elevations of SGOT or
SGPT, bilirubinemia 5. CNS reactions include headache, hyperactivity, nervousness, sleep
disturbances, confusion, hypertonia, and dizziness were reported. Local phlebitis occurs rarely
following intravenous administration but can be minimized by slow injections over 2-4 minutes.
Potentially hazardous interactions: No impairment of renal function or increased nephrotoxicity
has been observed in man after simultaneous administration of ceftriaxone with diuretics, or
with aminoglycosides. A possible disulfiram-like reaction may occur with alcohol. Other
significant interactions: Ceftron® doesn’t interfere with the protein binding of bilirubin.
Simultaneous administration of probenecid doesn’t alter the elimination of ceftriaxone.
Potentially useful interactions: Experimentally, in vivo, ceftriaxone has been shown to enhance
bacterial killing by human neutrophils.
USE IN PREGNANCY AND LACTATION
Ceftron® has not been associated with adverse effects on fetal development in laboratory
animals, but its safety in human pregnancy has not been established. Therefore, it should not be
used in pregnancy unless absolutely indicated. Because ceftriaxone is distributed into milk, the
drug should be used with caution in nursing women.